Voltafas Mebo Burn Fast Pain Relief Healing Cream Leaves No Marks 15 Grams

Product Information

There is low‐certainty evidence that a skin substitute may slightly reduce time to partial (i.e. greater than 90%) wound healing, compared with a non‐specified antibacterial agent (MD –6.00 days, 95% CI –8.69 to –3.31; 1 study, 34 participants). Insufficient reporting of attrition/exclusions to permit judgement of low or high risk of bias (e.g. number randomised not stated, no reasons for missing data provided). face OR facial OR nose OR ear OR ears) AND burn [Title] AND topical OR local OR ointment OR dressing OR bandage OR lotion OR cream OR gel OR solution [Interventions]

EBSCO CINAHL Plus (Cumulative Index to Nursing and Allied Health Literature; 1937 to 18 December 2019).Beta-sitosterol 0.25%. The base of the ointment is composed of sesame oil and beeswax, 18 amino acids, 4 major fatty acids, vitamins and polysaccharides. other sources of bias: baseline similarity, co‐interventions, compliance, similar timing of outcome assessment. For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate. Need for surgery (mean number of surgical procedures): I: 1.2 (SE 0.1) C: 1.0 (SE 0); reported P < 0.05. Four additional potentially eligible studies were excluded in this update. Full‐text analysis resulted in four exclusions because the study was not an RCT ( Schulz 2016), or did not involve facial burns ( Aboelnaga 2018; Hundeshagen 2018; Moenadjat 2008).

This is an update of a Cochrane Review first published in 2013 ( Hoogewerf 2013b). The updated searches (18 December 2019), identified, after initial deduplication, 527 unique records. Quotes: "they were divided in two group" (methods section), and "This might not be the first randomised trial…" (discussion). All eleven patients underwent prompt surgical debridement with initiation of triple broad-spectrum antibiotic therapy. Debridement was radical and wide, in line with the common practice in treating FG, as reported by Corman et al., Time to complete wound healing (mean): I: 10.05 (SD 2.3); C1: 10.35 (SD 2.8); C2: 12.05 (SD 2.4), reported P < 0.05.The study protocol is available and all of the study's prespecified (primary and secondary) outcomes that are of interest in the review have been reported in the prespecified way. dressing* or pad or pads or gauze or tulle or film or bead or foam* or non‐adherent or non adherent or hydrocolloid* or hydrofibre* or hydrogel* or alginate* or plaster* or compress or absorb* or dextra* or silicon* or amnion*):ti,ab,kw Although originally described as idiopathic, FG has an identifiable cause in almost 95% of cases. The necrotizing process commonly originates from an infection in the anorectum, the urogenital tract, or the skin of the genitalia. The essential components found in Mebo Scar ointment assist in recovering physiological function of skin, reconstruction of the local physiological environment, regeneration of sebaceous glands, restraining the hyperplasia of fibroblast cells, and removing the scars all over the body. OR #14 OR #15 OR #16 OR #17 OR #21 OR #22 OR #24 OR #25 OR #27 OR #28 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 AND INREGISTER

There is mixed‐certainty evidence that there is no clear difference in time to complete wound healing (no overall effect size available). One study revealed moderate Wound healing was variously measured and reported including: time to complete wound healing time to 90% wound healing, or change in wounds and percentage of wound healed during follow‐up. Most studies reported time to wound healing, but only two studies used survival methods (the appropriate approach to statistical analysis of time to event data) ( Ang 2000; Oen 2012). For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size. Time to complete epithelisation, pain, wound infection, hypersensitivity reaction, need for skin grafting face OR facial OR nose OR ear OR ears) AND scalds [Title] AND topical OR local OR ointment OR dressing OR bandage OR lotion OR cream OR gel OR solution [Interventions]

General Application of MEBO Burn and Wound Ointment

Change in wound surface area over time, or the proportion of the burn wound completely healed (epithelialised) in a specific time period (as defined by the trial authors). In case of unclear definition of healing, data were included but this was mentioned.